Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Brooks Laboratories is currently trading at Rs 16.80, up by 0.25 points or 1.51% from its previous closing of Rs. 16.55 on the BSE.
The scrip opened at Rs 16.80 and has touched a high and low of Rs. 16.80 and Rs 16.80 respectively.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 131.10 on 05-Sep-2011 and a 52 week low of Rs. 15.20 on 25-Nov-2011.
Last one week high and low of the scrip stood at Rs 17.30 and Rs 16.30 respectively. The current market cap of the company is Rs. 27.00 crore.
The promoters holding in the company stood at 60.77% while Non-Institutions hold 39.23% respectively.
Brooks Laboratories has received an approval for manufacture of Doripenem Monohydrate injection from Directorate General of Health Service. The company is all set to manufacture this drug within this fiscal year.
Doripenem is a broad spectrum anti-bacterial agent of carbapenem family. Growing bacterial resistance is major cause of concern for researchers as it contributors to increase in mortality, morbidity and treatment cost. Doripenem is an ultra broad spectrum anti bacterial agent of carbepenem family used to treat in complicated intra-abdominal infections and complicated urinary tract infections, including complicated and uncomplicated pylenephritis and cases with concurrent bacteremia.
Brooks Laboratories is into pharmaceutical contract research and manufacturing services. It is having wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General Dry powder Injectables, Ampoules and Liquid vials, Dry Syrups and Tablets etc.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1532.85 |
| Dr. Reddys Lab | 5812.50 |
| Cipla | 1403.90 |
| Zydus Lifesciences | 1104.45 |
| Lupin | 1661.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
